Analysis: Failed Alzheimer's drug may get second chance

CHICAGO Wed Aug 8, 2012 10:33am EDT

Holocaust survivor Betty Stein, 92, (R) is helped by coach Irina Jestkova as she plays ping pong at a program for people with Alzheimer's and dementia at the Arthur Gilbert table tennis center in Los Angeles, California June 15, 2011. REUTERS/Lucy Nicholson

Holocaust survivor Betty Stein, 92, (R) is helped by coach Irina Jestkova as she plays ping pong at a program for people with Alzheimer's and dementia at the Arthur Gilbert table tennis center in Los Angeles, California June 15, 2011.

Credit: Reuters/Lucy Nicholson

Related Topics

CHICAGO (Reuters) - Pfizer and Johnson & Johnson's Alzheimer's drug failed to help patients showing early signs of the disease, but it could get another chance as scientists test whether the devastating illness should be treated before symptoms appear.

Pfizer and J&J said on Monday that they were scrapping large-scale clinical trials of the experimental drug bapineuzumab in patients with mild to moderate Alzheimer's disease, after the drug failed to improve their memory or thinking skills.

While disappointing to millions of Alzheimer's patients and their families, the result was no surprise to researchers or investors who had anticipated a slim chance of success.

That's because scientists now view Alzheimer's as a decades-long process in which the toxic protein beta amyloid gradually builds up in the brain before dementia sets in.

They believe the best hope now is testing drugs much earlier in this process, before the disease has done too much damage. But some fear that companies like Pfizer and J&J may balk over the long haul after spending billions on failed experiments.

"Even though the scientific rationale might still be valid and strong and not adequately tested in the phase of the disease where you might expect the therapy to work, that may be lost to investors," said Dr. Ronald Petersen, director of the Mayo Clinic Alzheimer's Disease Research Center in Rochester, Minnesota. "I hope that is not the case."

Pfizer and J&J said they do not yet have plans to test the compound in people at risk for Alzheimer's, but who do not have symptoms. The companies, which are developing the drug together, are due to present data next month showing whether it reduced levels of beta amyloid in the brain as well as other so-called biomarkers, and that will determine whether it can be used in earlier trials, researchers said.

"The jury is still out about the earlier use of bapineuzumab and other medications like it for earlier stages of the disease," said Dr. Steven Salloway of Brown University in Providence, Rhode Island, who chaired the scientific steering committees for late-stage studies of the treatment.

These so-called biomarker results will be released on September 11 at a medical meeting in Stockholm.

"If the biomarkers move in a positive direction, that is encouraging with regard to moving earlier," said Petersen. "Ultimately, you'd like to go into asymptomatic patients."

THE NEW WAVE

Alzheimer's is the most common form of dementia, affecting nearly 36 million people worldwide, and its prevalence is expected to grow as the world's population lives longer.

Current drugs only treat symptoms and none have yet been able to keep the fatal disease from progressing. That has proven a tantalizing prospect for drugmakers, as a success would be worth billions of dollars.

The repeated failure to find something that works is also costly: J&J said on Monday it would take a charge of up to $400 million over its bapineuzumab research. Eli Lilly and Co will present results on a similar drug, solanezumab, in the coming weeks. Investors see the probability of success as less than 11 percent, according to a survey by ISI Group.

Dr. Husseini Manji, global head of neuroscience drug development at J&J's Janssen research unit, said the company remains committed to Alzheimer's research and will scour the bapineuzumab trials for information that will help plan the next set of studies.

"When we got into this, we realized it was one of the most challenging things we could take on," he said in an interview. "You hope your first approach works, but we are certainly going to learn a hell of a lot from this data."

Among the next wave of clinical trials, the Dominantly Inherited Alzheimer's Network (DIAN) will test several drugs in patients, who are genetically predisposed to develop the disease at an early age.

People in these families have a 50 percent chance of inheriting one of three genes that cause early Alzheimer's. Most develop symptoms before age 45.

Dr. Randall Bateman of Washington University School of Medicine in St. Louis, who runs the drug-testing arm of that study, said last month the trial would select drugs after results of bapineuzumab and solanezumab are announced.

Dr. John Morris of Washington University, who leads the overall study, said the failed Phase 3 results of bapineuzumab do not eliminate it from consideration for DIAN trials.

"The most important information from the failed bapi (bapineuzumab) studies for DIAN will be whether there are unanticipated safety issues," Morris said in an e-mail. Brown's Salloway said he saw no new safety issues.

The trials terminated by Pfizer and Johnson & Johnson delivered the drug as an intravenous infusion. But they will continue with a shot form now being tested in a Phase 2 clinical trial in patients with mild to moderate disease.

Salloway said the companies thought it was worthwhile to gather data on how this form of the drug works at attacking the underlying disease, though it is unlikely to work for patients already exhibiting symptoms.

A shot would be more convenient than an IV infusion, which may prove useful for future trials. Patients in the Phase 2 study will be informed of the Phase 3 results, and will need to sign consent forms to continue in the study, Salloway said.

Scientists are also testing crenezumab, made by Roche Holding AG's Genentech unit, in a large family of people in Colombia who develop early onset Alzheimer's. And while researchers may fear the profit equation may turn against them, patient groups believe the business rationale will be there for the duration.

"You are going to learn from every study you do. That will get you to the end of the road eventually," said William Thies, chief medical and scientific officer at the Alzheimer's Association. "Alzheimer's disease still has a profile that makes one think it is treatable, has a reasonably large market and should continue to attract attention from drug companies."

(Editing by Michele Gershberg and; Leslie Gevirtz)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (2)
SuefromSault wrote:
Nuts, it is fairly obvious by now that beta amyloid
is a side effect of what produces memory
loss NOT the problem.

Aug 08, 2012 1:56pm EDT  --  Report as abuse
umojaresearch wrote:
“Whenever you go back and look retrospectively, you find things that could be a mirage,” said Michael Krensavage, founder of Krensavage Asset Management in New York. He said the number of patients in the final analysis was too small to make a clear judgment on bapineuzumab’s effectiveness”.The drug very well may work, but there isn’t the data to prove that.”

Both groups tested with the drug reported serious side effects, among them a brain-swelling condition called vasogenic edema. Patients receiving higher doses also didn’t record stronger benefits, researchers said at the meeting. Usually a drug that works will have stronger effects in higher doses, Krensavage said.

When drugs are reconsidered, what we should seriously consider is, how many billions of dollars will able to be made? when the “Baby Boomers” may amount to at least six million people and a larger proportion of those suffering from Alzheimer’s, we can each draw our own conclusion why this dangerous drug is being reconsidered. Drug companies stand to make billions.

Ref:

1. Politics in Healing: The Suppression and Manipulation of American Medicine by Daniel Haley
2. The Persecution and trial of Gaston Naessens: The True Story of The Efforts to Suppress an Alternative Treatment for Cancer, AIDS and Other Immunologically Based Diseases, by Christopher Bird.
5. “Full Disclosure”, by Dr. Gary L Glum (AIDS Evidence of Dr. John Seale
6. Nutrition Against Disease, Roger J. Williams
7. Racketeering in Medicine, The Suppression of Alternatives, James P. Carter, M.D., Dr.P.H
8. DVD, Cancer, The Forbidden Cures, Massimo Mazzucco
9. DVD, Dying To Have Known, The Evidence Behind Natural Healing, Steve Kroschel
10. Murder By Injection: The Story of The Medical Conspiracy Against America, by Eustace Mullins
12. The Gerson Therapy: The Proven Nutritional Program for Cancer and Other Illnesses, by Charlotte Gerson and Morton Walker
13. A Cancer Therapy: Results of Fifty Cases and The Cure of Advanced Cancer by Diet Therapy, by Dr. Max Gerson
14. The Budwig Cancer & Coronary Heart Disease Prevention Diet: The Revolutionary Diet from Dr. Johanna Budwig, the Woman Who Discovered Omega-3s, by Dr. Johanna Budwig
15. Cancer: The Problem and The Solution, by Dr. Johanna Budwig
16. Royal R. Rife: Humanitarian, Betrayed and Persecuted, by Gerald F. Foye
17. The Cancer Cure That Worked: 50 Years of Suppression, by Barry Lynes
18. Suppressed Medical Science, by Jack Phillips
19. You Don’t Have To Die! By Harry M. Hoxsey
20. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted And The Startling Implications for Diet, Weight Loss And Long-Term Health, by T. Colin Campbell

Aug 08, 2012 10:37pm EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.